Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 13/20 | 0.51 |
| ▸ | EDNRA | P25101 | 13/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069871 | 0.92 | EDNRB (0.46) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7828049 | 0.90 | EDNRB (0.48) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7065375 | 0.89 | EDNRB (0.55) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7071220 | 0.88 | ALDH1A1 (0.54) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7066520 | 0.87 | EDNRB (0.46) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7068523 | 0.87 | ALDH1A1 (0.48) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7067319 | 0.86 | EDNRB (0.55) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7069708 | 0.85 | ALDH1A1 (0.51) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7068590 | 0.85 | ALDH1A1 (0.51) | EDNRBEDNRAALDH1A1L3MBTL1HTT | |
| SCHEMBL7065776 | 0.85 | EDNRA (0.50) | EDNRBEDNRAALDH1A1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
| EP-0811001-B1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0811001-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-10 | — | — | EP | claimed |
| WO-1996026195-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-08-29 | — | — | WO | claimed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | disclosed |
| EP-0811001-B1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-0811001-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| WO-1996026195-A1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885ALDH1A1 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.